Patients with chronic spontaneous urticaria improved early, with benefits lasting through the 52-week follow-up for those who ...

In September 2024, the FDA approved a new biosimilar for treating retinal conditions, marking a significant development in ...

If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, look no further than the iShares Biotechnology ETF (IBB), a passively managed exchange traded fund ...

The US Food and Drug Administration has approved dupilumab as an add-on maintenance therapy for adults whose chronic ...

Sanofi SNY and partner Regeneron REGN announced that the FDA has approved their blockbuster drug, Dupixent, for its sixth ...

Regeneron (REGN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan ...

On August 23, 2024, the FDA approved Amgen’s aflibercept biosimilar PAVBLU (aflibercept-ayyh), a biosimilar of Regeneron’s EYLEA®. According to the approval letter, “Pavblu is indicated for ...

Before Oct. 7, I hadn't wanted to play "T'filah," by Lera Auerbach. Now, I hope that it can bring us a little closer together ...